Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227287 · ClinicalTrials.gov registry record
ADH1 and ADH2 Disease Monitoring Study (DMS)
A clinical trial of Autosomal Dominant Hypocalcemia, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- Active
- Registry status
- 95
- Enrollment target
- 20
- Study locations
NCT05227287 is a study of Autosomal Dominant Hypocalcemia that is active but no longer recruiting, run by Calcilytix Therapeutics, Inc., a BridgeBio company. The registered enrollment target is 95 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT05227287, a study of Autosomal Dominant Hypocalcemia, is active but no longer recruiting, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- ACTIVE NOT RECRUITING
- Registry status
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.
Conditions Studied
Study Locations (20)
Other
- Aarhus University Hospital - Aarhus
- Helsinki University Hospital (HUS) - The New Children's Hospital - Helsinki
- CHU de Lille - Lille
- Endokrinologikum Gottingen - Göttingen
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Ohio State University Medical Center (OSUMC) - Columbus
Auvergne-Rhône-Alpes
- HCL Hopital Femme Mere Enfant - Bron
- HCL Hopital Edouard Herriot - Lyon
California
- University of California, San Francisco (UCSF) - Benioff Children's Hospital - Oakland - Oakland
Colorado
- Children's Hospital Colorado - Aurora
Florida
- Nemours Children's Clinic - Jacksonville
Indiana
- Indiana University (IU) School of Medicine - University Hospital - Indianapolis
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227287
The ClinicalTrials.gov registry entry for NCT05227287 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calcilytix Therapeutics, Inc., a BridgeBio company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autosomal Dominant Hypocalcemia appearing as the primary indexed condition, and to 0 interventions.
NCT05227287 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Ohio, Auvergne-Rhône-Alpes.
Frequently Asked Questions
What is clinical trial NCT05227287 about?
NCT05227287 is a clinical study titled "ADH1 and ADH2 Disease Monitoring Study (DMS)". A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospec...
What is the current status of trial NCT05227287?
This trial is currently active not recruiting. The enrollment target is 95 participants. The study started on 2022-01-20. Estimated completion is 2028-12.
What conditions does trial NCT05227287 study?
This clinical trial studies the following conditions: Autosomal Dominant Hypocalcemia.
Who is sponsoring clinical trial NCT05227287?
This trial is sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05227287 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.